chr2-165992387-C-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP2PP3_ModeratePP5
The NM_001165963.4(SCN1A):c.4888G>A(p.Val1630Met) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1630L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001165963.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN1A | NM_001165963.4 | c.4888G>A | p.Val1630Met | missense_variant | 29/29 | ENST00000674923.1 | NP_001159435.1 | |
LOC102724058 | NR_110598.1 | n.176-23226C>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN1A | ENST00000674923.1 | c.4888G>A | p.Val1630Met | missense_variant | 29/29 | NM_001165963.4 | ENSP00000501589 | P4 | ||
SCN1A-AS1 | ENST00000651574.1 | n.193-23226C>T | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 04, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the Val1630 amino acid residue in SCN1A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 23195492). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SCN1A protein function. ClinVar contains an entry for this variant (Variation ID: 68556). This missense change has been observed in individual(s) with Dravet syndrome (PMID: 17561957). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 1630 of the SCN1A protein (p.Val1630Met). - |
Severe myoclonic epilepsy in infancy;C1858673:Generalized epilepsy with febrile seizures plus, type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Apr 25, 2020 | The p.Val1630Met variant in SCN1A has been reported in a patient affected with familial severe myoclonic epilepsy of infancy [PMID: 17561957]. Patient’s EEG results showed generalized spike-wave & multifocal [supplemental table 3 of www.ncbi.nlm.nih.gov/books/NBK1318/]. The p.Val1630Met variant is absent from the gnomAD database indicating it is an extremely rare allele. The variant affects an evolutionarily conserved residue located in the D4/S3-S4ex extracellular region of the SCN1A protein [PMID: 18804930] and is predicted deleterious by multiple in silico prediction tools. Two different missense variants affecting the same p.Val1630 residue (p.Val1630Glyand p.Val1630Leu) have been reported in individuals affected with SCN1A-associated disorders [PMID: 27465585; PMID: 23195492; PMID: 22092154]. However, functional studies have not been performed to evaluate the potential pathogenicity of variants affecting the residue p.V1630 of SCN1A. Based on the available evidence, the p.Val1630Met variant is assessed as a variant of uncertain significance suspicious of likely pathogenic. - |
Severe myoclonic epilepsy in infancy Other:1
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at